Peter Georgiev
Peter Georgiev has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
- Arlene H. Sharpe
Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA
20 shared publications - Marcia C. Haigis
Department of Cell Biology, Blavatnik Institute, Harvard Medical School, Boston, USA
20 shared publications - Alison E. Ringel
Ragon Institute of Mass General Brigham, MIT and Harvard, Cambridge, MA, USA
19 shared publications - Jefte M. Drijvers
Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, Massachusetts
19 shared publications - Amy Y. Huang
Dana-Farber Cancer Institute, Boston, MA, USA
18 shared publications - Brian C. Miller
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
18 shared publications
Latest Publications
- 6 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (125)
Collateral damage…or is love really blind?
Bystander T cells eradicate tumors in the absence of antigen recognition.
- 6 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 11 (125)
Collateral damage…or is love really blind?
Bystander T cells eradicate tumors in the absence of antigen recognition.
- Open Access
- 8 July 2026
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 14
Depletion of extracellular asparagine impairs self-reactive T cells and ameliorates autoimmunity in a murine model of multiple sclerosis
Amino acids play critical roles in the activation and function of lymphocytes. Here we show that the non-essential amino acid, asparagine, is essential for optimal activation and proliferation of CD4 + T cells. We demonstrate that asparagine depletion at different time points after CD4 + T cell activation reduces mitochondrial membrane potential and function. Furthermore, asparagine depletion at specific time points during CD4 + T cell differentiation reduces cytokine production in multiple CD4 + T cell subsets. In an adoptive transfer model of experimental autoimmune encephalomyelitis (EAE), myelin oligodendrocyte-specific pathogenic T helper 17 cells differentiated under Asn-deficient conditions exhibited reduced encephalitogenic potential and attenuated EAE severity. In a model of EAE induced by active immunization, therapeutic depletion of extracellular Asn significantly reduced disease severity. These results identify asparagine as a key metabolic regulator of the pathogenicity of autoreactive CD4 + T cells and suggest that targeting asparagine metabolism may be a novel therapeutic strategy for autoimmunity.
- 8 July 2026
- Published by eLife Sciences Publications, Ltd in eLife
- Vol. 14
Open AccessDepletion of extracellular asparagine impairs self-reactive T cells and ameliorates autoimmunity in a murine model of multiple sclerosis
Amino acids play critical roles in the activation and function of lymphocytes. Here we show that the non-essential amino acid, asparagine, is essential for optimal activation and proliferation of CD4 + T cells. We demonstrate that asparagine depletion at different time points after CD4 + T cell activation reduces mitochondrial membrane potential and function. Furthermore, asparagine depletion at specific time points during CD4 + T cell differentiation reduces cytokine production in multiple CD4 + T cell subsets. In an adoptive transfer model of experimental autoimmune encephalomyelitis (EAE), myelin oligodendrocyte-specific pathogenic T helper 17 cells differentiated under Asn-deficient conditions exhibited reduced encephalitogenic potential and attenuated EAE severity. In a model of EAE induced by active immunization, therapeutic depletion of extracellular Asn significantly reduced disease severity. These results identify asparagine as a key metabolic regulator of the pathogenicity of autoreactive CD4 + T cells and suggest that targeting asparagine metabolism may be a novel therapeutic strategy for autoimmunity.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S6 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S6 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S7 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S7 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S8 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S8 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S2 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity